Daniel joined Sofinnova BioEquities as an Analyst in 2026. He focuses on public investments in global biotechnology and pharmaceutical companies.
Prior to joining Sofinnova, Daniel spent four years on the sell-side covering SMid Biotechnology, most recently as an Associate at Goldman Sachs.
Daniel received his PhD in Neurobiology from Caltech and his MD from National Yang Ming University, Taiwan.